|
|
|
| Analysis of the effect of Zoledronic Acid combined with Simvastatin in the treatment of patients with type 2 diabetes and osteoporosis |
| WU Bo XIE Ming |
| Department of Endocrinology and Hematology,the Second People′s Hospital of Zhaoqing,Guangdong Province,Zhaoqing 526000,China |
|
|
|
|
Abstract Objective To analyse the effect of Zoledronic Acid combined with Simvastatin in the treatment of patients with type 2 diabetes(T2DM)and osteoporosis.Methods A total of 64 patients with T2DM and osteoporosis admitted to the Second People′s Hospital of Zhaoqing from October 2018 to July 2019 were selected as the research subjects.They were divided into the combination group(32 cases)and the single-drug group(32 cases)according to the odd and even number grouping method.The single-drug group was treated with Zoledronic Acid,and the combination group was treated with Simvastatin on the basis of the single-drug group.The clinical bone pain symptoms,bone biochemical indicators,density of different parts of the bone,and adverse reactions between the two groups were compared.Results The clinical bone pain symptoms of the combination group were milder than those of the single-drug group,and the differences were statistically significant(P<0.05).There were no significant differences in serum osteocalcin(BGP),bonespecific alkaline phosphatase(BALP),osteoprotegerin(OPG)and blood phosphorus(P)between the two groups before treatment(P>0.05).After 8 months of treatment,the levels of BGP and BALP of the two groups were lower than those before treatment,and those indicators in the combination group were lower than those of the single-drug group; the levels of OPG and phosphorus were both higher than those before treatment,and the two indicators in the combination group were higher compared with those in the single-drug group,and the differences were statistically significant(P<0.05).There were no significant differences in the bone mineral density of the lumbar spine,femoral neck and Ward triangle between the two groups before treatment(P>0.05); after 8 months of treatment,the bone mineral density of the lumbar spine,femoral neck and Ward triangle of the two groups were all higher than those before treatment,and the combination group was higher than that in the group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions after treatment in the combined group was lower than that in the single-drug group,and the difference was statistically significant(P<0.05).Conclusion The combination of Simvastatin and Zoledronic Acid in the treatment of patients with T2DM and osteoporosis can improve their bone biochemical indicators,increase bone density,and reduce bone pain symptoms and adverse drug reactions.
|
|
|
|
|
|
| [1] |
李达春，周德勇，邹耀，等.围绝经期骨质疏松症合并2 型糖尿病患者糖代谢与骨代谢的相关性分析[J].中国骨质疏松杂志，2020，26（6）：893-897.
|
| [2] |
陈清河，曾维铨，黄少辉，等.碳酸钙D3、骨化三醇联合唑来膦酸对2 型糖尿病合并原发性骨质疏松症患者骨密度和骨痛的影响[J].中国骨质疏松杂志，2020，26（2）：202-204，226.
|
| [3] |
林文刁.唑来膦酸结合辛伐他汀治疗老年糖尿病并骨质疏松的效果探析[J].实用妇科内分泌电子杂志，2018，5（26）：67-68.
|
| [4] |
倪利华.糖尿病性骨质疏松症的研究进展[J].临床与病理杂志，2020，40（7）：1897-1901.
|
| [5] |
柳淇元.唑来膦酸预防股骨粗隆间骨折内固定术后局部骨质疏松的效果研究[J].中国现代药物应用，2020，14（15）：23-25.
|
| [6] |
李慧，肖欢，黄明龙，等.阿托伐他汀钙联合唑来膦酸钠治疗对老年骨质疏松患者的临床效果及患者骨密度、骨钙素水平变化[J].中国老年学杂志，2020，40（13）：2830-2833.
|
| [7] |
王强，张志超，张慧明，等.唑来膦酸对老年骨质疏松性椎体压缩骨折患者BALP 和BG 的影响及疗效[J].河北医科大学学报，2020，41（4）：463-466.
|
| [8] |
张俊越，龚维明.唑来膦酸注射液治疗骨质疏松不良反应的研究进展[J].山东医药，2020，60（13）：107-110.
|
| [9] |
杨晓东.唑来膦酸联合辛伐他汀对骨质疏松的影响分析[J].中国伤残医学，2020，28（3）：46-47.
|
| [10] |
张佳暄.唑来膦酸联合辛伐他汀对骨质疏松的影响分析[J].中国伤残医学，2020，28（7）：56-57.
|
| [11] |
贾忠雄，江维，张晓军，等.唑来膦酸治疗骨质疏松症的研究进展[J].现代医药卫生，2020，36（15）：2419-2422.
|
| [12] |
任华，张之梁，蔡伟，等.唑来膦酸联合碳酸钙D3治疗糖尿病性骨质疏松症的疗效及其对患者骨密度和骨代谢指标的影响[J].河北医学，2020，26（1）：45-50.
|
| [13] |
于冬冬，赵丹阳，杨鸫祥，等.辛伐他汀通过NF-κB 通路抑制破骨细胞的分化[J].中国医科大学学报，2020，49（3）：198-202，208.
|
| [14] |
汤舒婷，段修杨.的比较研究老年高血压合并骨质疏松患者口服依那普利联合辛伐他汀对骨密度及骨代谢指标的效果[J].世界最新医学信息文摘（连续型电子期刊），2019，19（97）：131，144.
|
| [15] |
李丽，韩芬.唑来膦酸联合辛伐他汀治疗2 型糖尿病合并骨质疏松患者的骨代谢状况分析[J].国际老年医学杂志，2018，39（3）：127-129，153.
|
|
|
|
